Breast Cancer Research and Treatment

, Volume 55, Issue 2, pp 187–197 | Cite as

Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT‐B

  • Lesley J Fallowfield
  • Samantha K Leaity
  • Anthony Howell
  • Sarah Benson
  • David Cella


Existing quality of life instruments do not include adequate items to measure the side effects and putative benefits of hormonal treatments given in breast cancer. We report the development and validation of an 18 item endocrine subscale (ES) to accompany a standardised breast cancer quality of life measure, the Functional Assessment of Cancer Therapy (FACT‐B) [1]. The FACT‐ES (FACT‐B plus ES) was tested initially on 268 women with breast cancer receiving endocrine treatments. Alpha coefficients for all subscales demonstrated good internal consistency (range α = 0.65–0.87). Test‐retest reliability of the ES indicated good stability (r = 0.93, p < 0.001). Advanced breast cancer patients' quality of life was high, showing the efficacy of endocrine therapy, but women with primary disease reported better physical, social, and functional well‐being and fewer breast cancer concerns. Most frequently reported symptoms were loss of sexual interest (31%), weight gain (25%), and hot flushes (24%). Significant differences were found between treatment groups for hot flushes and vaginal dryness. Two assessments of the instrument's responsiveness to change were made; 32 women in a clinical trial of endocrine therapy and 18 women without breast cancer taking HRT completed the FACT‐ES at baseline, 4, 8, and 12 weeks. Trial patients reported significantly more symptoms at 8 and 12 weeks than at baseline. Women taking HRT reported significantly fewer or less severe symptoms than at baseline. In conclusion the FACT‐ES has acceptable validity and reliability and is sensitive to clinically significant change, making it suitable for clinical trials of endocrine therapy.

breast cancer endocrine therapy FACT‐B FACT‐ES quality of life 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Brady MJ, Cella DF, Mo F, et al.: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast (FACT-B) quality of life instrument. J Clin Oncol 15: 974–986, 1997Google Scholar
  2. 2.
    Howell A, Downey S, Anderson E: New endocrine therapies for breast cancer. Eur J Cancer 32A(4): 576–588, 1996Google Scholar
  3. 3.
    Jonat W, Howell A, Blomqvist C, et al.: A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer 32A(3): 404–412, 1996Google Scholar
  4. 4.
    Couzi RJ, Helzlsouer K, Fetting JH: Prevalence of menopausal symptoms among women with a history of breast cancer and attitudes toward estrogen replacement therapy. J Clin Oncol 13: 2737–2744, 1995Google Scholar
  5. 5.
    Love RR, Cameron L, Connell BL: Symptoms associated with tamoxifen treatment in postmenopausal women. Archives Int Med 151: 1842–1847, 1991Google Scholar
  6. 6.
    Kornblith AB, Hollis DR, Zuckerman E: Effect of megestrol acetate on quality of life in a dose-response trial in women with advanced breast cancer. J Clin Oncol 11: 2081–2089, 1993Google Scholar
  7. 7.
    Hayes DF, Van Zyl JA, Hacking A: Randomized comparison of tamoxifen with two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 13: 2556–2566, 1995Google Scholar
  8. 8.
    Leonard RCF, Lee L, Harrison ME: Impact of side effects associated with endocrine treatments for advanced breast cancer: Clinicians' and patients' perceptions. The Breast 5: 259–264, 1996Google Scholar
  9. 9.
    Hopwood P: Living with advanced breast cancer: Development and application of a clinical checklist for patients on endocrine therapy. The Breast 7: 14–21, 1998Google Scholar
  10. 10.
    Daly E, Gray A, Barlow D, McPherson K, Roche M, Vessey M: Measuring the impact of menopausal symptoms on quality of life. Br Med J 307: 836–840, 1993Google Scholar
  11. 11.
    Canney PA, Hatton MQF: The prevalence of menopausal symptoms in patients treated for breast cancer. Clin Oncol 6: 297–299, 1994Google Scholar
  12. 12.
    Cella D: Manual for the Functional Assessment of Cancer Therapy (FACT) quality of life instrument (Version 4). Evanston Northwestern Healthcare, Evanston, II, USA, 1997Google Scholar
  13. 13.
    Streiner DL, Norman GR: Health Measurement Scales. Oxford University Press, New York, 1989Google Scholar
  14. 14.
    Nunnally JC: Psychometric Theory, 2nd edition. McGraw-Hill, New York, 1978Google Scholar
  15. 15.
    Cella DF, Bonomi AE, Lloyd SR, Tulskey DS, Kaplan E, Bonomi P: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12: 199–220, 1995Google Scholar
  16. 16.
    Bonomi AE, Cella DF, Hahn EA, et al.: Multilingual translation of the Functional Assessment of Cancer Therapy (FACT) quality of life measurement system. Qual Life Res 5: 309–320, 1996Google Scholar

Copyright information

© Kluwer Academic Publishers 1999

Authors and Affiliations

  • Lesley J Fallowfield
    • 1
  • Samantha K Leaity
    • 1
  • Anthony Howell
    • 2
  • Sarah Benson
    • 2
  • David Cella
    • 3
  1. 1.CRC Psychosocial Oncology Group, Department of OncologyUniversity College London Medical SchoolUK
  2. 2.CRC Department of Medical Oncology, Christie HospitalUniversity of ManchesterUK
  3. 3.Center on Outcomes, Research and EducationEvanston Northwestern Healthcare, Northwestern UniversityUSA

Personalised recommendations